Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Lung Cryablation Procedures

Validate the Feasibility and Safety of the Robot System by Investgating the CT-fluoroscopy Guidance in Percutaneous Lung Cryablation Procedures of Participants With Lung Cancer

This study aims to investigate whether the interventional robot can be well and safely used for percutaneous lung cryoablation in patients with lung cancer. The robot allows radiologists to remotely control the needle insertion process under CT fluoroscopy guidance.

The main questions this study aims to answer are:

  1. Whether the robot-assisted Cryoablation method can achieve complete the coverage of preoperatively planned ablation areas;
  2. Whether the robot-assisted Cryoablation method can improve the success rate for radiologists to insert the needle into the target lesion area without additional needle adjustment;
  3. Whether the robot-assisted Cryoablation method can reduce puncture time, ablation time and procedure time;
  4. Whether the robot-assisted Cryoablation method can decrease the patient's complication occurrence rate;
  5. Whether the robot-assisted Cryoablation method can obtain decent Evaluation of system performance.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Lung cancer is the leading cause of morbidity and mortality of malignant tumors.

The surgical resection of lung lobes is the standard treatment for stage I non-small cell lung cancer (NSCLC), with proven long-term cure rates and survival. However, more than 20% of patients are not eligible for surgical treatment due to comorbidities or poor underlying lung reserve.

With the development of minimally invasive interventional field, lung cancer cryoablation has also become an established tool for the treatment of early stage lung cancer and palliative treatment of advanced lung cancer in recent years.

However, the image-guidance cryoablation method still faces the following challenges:

  1. Lack of real-time and accurate information during the needle insertion process, including puncture force, needle deformation, soft tissue deformation, and needle arrival position;
  2. Multiple scans during the puncture are needed to determine whether the needle has successfully reached the target area, which leads to prolonged operation time, easily induces complications and increases the radiation dose to the physicians.
  3. The accuracy of needle insertion is highly affected by the patient's respiration movement causing the multi-directional nonlinear displacement and deformation of tissues and organs (movement, rotation, etc.), resulting in the drift of the tumour position. Eventually, it is difficult for radiologists to reach the target position, resulting in insufficient ablation areas and increased probability of cancer recurrence.
  4. The physiological trembling of the radiologist's hand will reduce the accuracy of puncture, and even lead to complications such as bleeding and pneumothorax
  5. The procedure is highly dependent on the ability and experience of radiologists.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Haipeng Yu, PhD
  • Phone Number: 0086-22-23340123
  • Email: jieruke@163.com

Study Contact Backup

Study Locations

    • Tianjin
      • Tianjin, Tianjin, China, 300060
        • Tianjin Medical University, Cancer Institute & Hospital
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Haipeng Yu, PhD
        • Sub-Investigator:
          • Xueling Yang, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Participants suffering from lung cancer and judged by the investigator to be indicated for cryoablation procedures;
  2. Participants voluntarily participate in this clinical study and sign the informed consent form;
  3. Participants cannot undergo surgical treatment due to contraindications to surgical resection of lung cancer;
  4. Participants can understand the study and cooperate with the study procedures, and are able to carry out follow-up observation as required.

Exclusion Criteria:

  1. Participants have diffuse lesions in both lungs that cannot be improved by ablative therapy;
  2. Participants suffer from extensive pleural metastases with massive pleural effusion;
  3. Participants have tumors adjacent to the mediastinal blood vessels, contrast allergy, or inability to cooperate, which makes it difficult to choose the route of needle insertion;
  4. Participants with lesions encircling blood vessels where ablation may lead to severe bleeding;
  5. Participants with severely impaired lung function, with maximal ventilation <40%;
  6. Participants with a low platelet count and severe coagulation abnormalities who cannot tolerate the procedure (anticoagulant therapy and/or anticoagulant medication should be discontinued for more than 1 week prior to ablation therapy);
  7. Participants with poor general condition (multiple metastases throughout the body, severe infections, high fever), obvious malignant disease, severe insufficiency of vital organ function, severe anemia, and disorders of nutritional metabolism that cannot be improved in the short term;
  8. Allergy to contrast media or anesthetics;
  9. Pregnant or breastfeeding women, or those who plan to have children during the clinical study;
  10. Participants with known addiction to drugs, alcohol, etc.;
  11. Participants with psychiatric disorders who have no self-control and are unable to communicate clearly;
  12. Participants who have participated in other drug, biologic, or medical device clinical studies without meeting the primary study endpoint timeframe prior to enrollment in this study;
  13. Any other conditions that the investigator deems unsuitable for participation in this clinical study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Singel arm
CT-fluoroscopy guided robot-assisted percutaneous lung Cryoablation group
During the procedure, the participants first undergo a CT scan. The radiologist plans the trajectories based on the registered preoperative CECT (contrast-enhanced computed tomography) and intraoperative CT. All participants then undergo navigation, localization, and establishment of cryoprobe trajectories using the interventional master-slave system. On the day of the procedure, the number of needle adjustments, number of cryoprobes used, puncture time, ablation time, and procedure time are recorded. The performance of the research device is evaluated by the radiologists. Postoperative complications of the participants are recorded 7±1 days postoperatively/on the day of discharge based on the postoperative CT scan (whichever comes first).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Technical success rate
Time Frame: The day of the procedure
After the cryoablation procedure, the radiologists evaluate the consistency of the postoperative ablation area derived from the immediate postoperative thoracic CT scan with the size of the preoperative planning area. If consistent, it is defined as a technical success. The technical success rate is defined as the ratio of the number of participants with technical success to the total number of enrolled participants.
The day of the procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The number of needle adjustments
Time Frame: The day of the procedure
The number will be counted when the needle tip angle is altered or the needle is retracted during the procedure.
The day of the procedure
Number of cryoprobes used
Time Frame: The day of the procedure
The number of cryoprobes used to complete cryoablation for a single target lesion during the cryoablation procedure.
The day of the procedure
Puncture time
Time Frame: The day of the procedure
Time from when the needle tip enters the skin to the completion of the puncture.
The day of the procedure
Ablation time
Time Frame: The day of the procedure
Time for the single lesion from when the cryoprobe arrives at the target to when the investigator judges the cryoablation is completed.
The day of the procedure
Procedure time
Time Frame: The day of the procedure
Time from when the patient is positioned to the completion of the ablation procedure as judged by the investigator.
The day of the procedure
Evaluation of system performance
Time Frame: The day of the procedure
Subjective evaluation from the radiologists regarding the commonly used functions, operation, stability, and convenience of the research device.
The day of the procedure
Compliations
Time Frame: 7±1 days postoperatively/on the day of discharge (whichever comes first).
Complications including pneumothorax, hemoptysis, bleeding, and other rare complications.
7±1 days postoperatively/on the day of discharge (whichever comes first).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Wenge Xing, Professor, Tianjin Medical University Cancer Institute and Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 15, 2024

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

February 28, 2025

Study Registration Dates

First Submitted

August 29, 2024

First Submitted That Met QC Criteria

August 29, 2024

First Posted (Actual)

September 3, 2024

Study Record Updates

Last Update Posted (Actual)

September 3, 2024

Last Update Submitted That Met QC Criteria

August 29, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • ZRIR-002-24-06

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.